Baseline Characteristics by Baseline N-BNP Level

Slides:



Advertisements
Similar presentations
Admission B-Type Natriuretic Peptide Levels and In-Hospital Mortality in Acute Decompensated Heart Failure Fonarow GC et al. J Am Coll Cardiol 2007; 49(19):
Advertisements

PAD Rehabilitation Toolkit A Guide for Healthcare Professionals Healthy Steps for Peripheral Artery Disease (PAD) Developed by AACVPR and the Vascular.
Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.
Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]
1 SECOND AUSTRALIAN NATIONAL BLOOD PRESSURE STUDY (ANBP-2) Enalapril/ACEI vs. HCTZ, n = 6,083 Randomized, open-label (blinded endpoint review) All CV events.
Economic evaluation of MRC/BHF Heart Protection Study Heart Protection Study Collaborative Group University of Oxford UK.
Lancet : doi: /S (08)60104-X Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from.
Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Systolic.
PEACE BNP: Omland, T. et al. J Am Coll Cardiol 2007; 50:205–14 Copyright ©2007 American College of Cardiology Foundation. Restrictions may apply. Prognostic.
HPS: Heart Protection Study Purpose To determine whether simvastatin reduces mortality and vascular events in patients with and without coronary disease,
Flow Diagram of the Main HOPE Trial and the HOPE-TOO Trial Extension The HOPE and HOPE-TOO Trial Investigators JAMA. 2005;293:
Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:
S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Selective heart rate reduction with ivabradine unloads the left ventricle in.
Serial Measurement of Monocyte Chemoattractant Protein-1 After Acute Coronary Syndromes Results From the A to Z Trial JA de Lemos, DA Morrow, SA Wiviott,
Baseline characteristics of participants presenting with or without peripheral artery disease (PAD) Heart Protection Study Group J Vasc Surg 2007;45:
Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:
ELIGIBILITY: MRC/BHF Heart Protection Study Increased risk of CHD death due to prior disease: Myocardial infarction or other coronary heart disease; Occlusive.
Baseline characteristics and eligibility criteria of participating trials Cholesterol Treatment Trialists’ (CTT) Collaborators Lancet 2005;366:
Date of download: 5/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Causal Assessment of Serum Urate Levels in Cardiometabolic.
Date of download: 5/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Omega-3 Polyunsaturated Fatty Acids and Cardiovascular.
Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Effect of Serelaxin on Cardiac, Renal, and Hepatic.
Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Effect of Serelaxin on Cardiac, Renal, and Hepatic.
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Effects of Habitual Coffee Consumption on Cardiometabolic.
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. Benefit of Anticoagulation Unlikely in Patients With Atrial.
Date of download: 6/22/2016 Copyright © The American College of Cardiology. All rights reserved. From: Genetic Inhibition of CETP, Ischemic Vascular Disease.
Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: Overview of the 2011 Food and Drug Administration.
Date of download: 6/26/2016 Copyright © The American College of Cardiology. All rights reserved. From: Clinical Effectiveness of CRT and ICD Therapy in.
Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Percutaneous Coronary Intervention Complications.
Date of download: 6/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Utility of B-type natriuretic peptide in the diagnosis.
Multivariate associations* between selected covariates and statin use Jawahar L. Mehta, et al. Am J Cardiol 2006;98:923–928.
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Making Sense of Statistics in Clinical Trial Reports:
Date of download: 9/19/2016 Copyright © The American College of Cardiology. All rights reserved. From: What resting heart rate should one aim for when.
US cost-effectiveness of simvastatin in 20,536 people at different levels of vascular disease risk: randomised placebo-controlled trial UK Medical Research.
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies  The Emerging.
Funding to Oxford University for MRC/BHF Heart Protection Study
Economic evaluation of MRC/BHF Heart Protection Study
All-cause mortality by treatment group
ELIGIBILITY: MRC/BHF Heart Protection Study
Adjusted relative mortality risk
Creatinine clearance (mL/min) n All-cause mortality (%)
Baseline characteristics of patients
Baseline characteristics of HPS participants by prior diabetes
INOVATE-HF Trial design: Patients with heart failure (HF) were randomized to device implant for vagus nerve stimulation (n = 436) versus optimal medical.
Biomarker-Guided HF Therapy: Is It Cost-Effective?
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies  The Emerging.
CV Risk Management in T2DM: What Did We Learn from ADA 2016?
Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy
Description of studies for pooled analyses
Lowering of SBP by 20 mm Hg Reduces Cardiovascular Risk by Half
TACTICS-HF Trial design: Patients with acute heart failure (reduced or preserved ejection fraction) were randomized to tolvaptan 30 mg at 0, 24, and 48.
Figure 2 Absolute difference in seasonal peak
Nat. Rev. Cardiol. doi: /nrcardio
Effects of Running on Chronic Diseases and Cardiovascular and All-Cause Mortality  Carl J. Lavie, MD, Duck-chul Lee, PhD, Xuemei Sui, MD, PhD, MPH, Ross.
MRC/BHF Heart Protection Study
Baseline Characteristics
Baseline Characteristics of Cardiovascular Risk Factors and Selected Dietary Variables in a Cohort of 22,881 Men and 35,091 Women to Quintile of Fish Intakes.
C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20 536 patients in the Heart Protection Study  Heart Protection.
Heart Protection Study Collaborative Group Lancet 2011;377:469-76
Estimated 5-year rate of a first major vascular event (MVE), major coronary event (MCE),or vascular death in univariate and multivariate risk subgroups.
Characteristics of 21,484 Patients With MI Who Survived for >30 Days After Discharge, by Calendar Year - Part I Soko Setoguchi, et al. J Am Coll Cardiol.
Cause of death Treatment-arm events, % (n=45 054)
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies  The Emerging.
Baseline Characteristics of Study Subjects
Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.
Emerging Risk Factors Collaboration. JAMA 2009;302:412-23
Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised.
Strategies for Optimizing Glycemic Control and Cardiovascular Prognosis in Patients With Type 2 Diabetes Mellitus  James H. O'Keefe, MD, Mohammad Abuannadi,
Baseline characteristics of the 1,842 men without coronary heart disease and the 230 men with a first coronary heart disease event during the 13-year.
Frankel DS, et al. J Am Coll Cardiol. 2009;53:754-62
Cohort and Community Surveillance Components
Presentation transcript:

Baseline Characteristics by Baseline N-BNP Level Heart Protection Study Collaborative Group. J Am Coll Cardiol 2007;49:311-9

Risk of Major Vascular Events, Stroke, Major Coronary Events, and Heart Failure Hospitalization or Death, by Baseline N-BNP Level Heart Protection Study Collaborative Group. J Am Coll Cardiol 2007;49:311-9

Relative Hazard of Vascular Events and Hospitalization or Death Due to HF by Baseline N-BNP Level (Adjusted for Differences in Baseline Characteristics) Heart Protection Study Collaborative Group. J Am Coll Cardiol 2007;49:311-9

Effects of Simvastatin on Vascular Events in Participants Subdivided by Baseline N-BNP Level Heart Protection Study Collaborative Group. J Am Coll Cardiol 2007;49:311-9

Absolute Benefits of Simvastatin Allocation on First MVE and First MCE, by Baseline N-BNP Level Heart Protection Study Collaborative Group. J Am Coll Cardiol 2007;49:311-9

Effects of Simvastatin on Vascular and Nonvascular Mortality in Participants Subdivided by Baseline N-BNP Level Heart Protection Study Collaborative Group. J Am Coll Cardiol 2007;49:311-9

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.